



**November 9, 2023**

To,  
Listing/ Compliance Department  
**BSE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**SCRIP CODE: 543748**

Dear Sir/Madam,

To,  
Listing/ Compliance Department  
**National Stock Exchange of  
India Limited**  
"Exchange Plaza", Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**SYMBOL: AARTIPHARM**

**Sub:** Recording of Earnings Conference Call  
**Ref:** Regulation 30 of the SEBI (LODR) Regulations  
2015

---

In continuation to our intimation dated November 4, 2023 regarding Investors/ Analyst Earnings Conference Call on the Financial Results of the Company for the Quarter and Half Year ended September 30, 2023, we would like to inform you that the audio recording of the said call has been uploaded on the Company's website. This can be accessed at link below:

Link: <https://www.aartipharmalabs.com/investors/Q2-FY24-Audio-Recording.mp3>

Please take the same on your records.

Thanking you,

Yours faithfully,  
**For AARTI PHARMALABS LIMITED**

NIKHIL NATU  
**COMPANY SECRETARY**  
ICSI M. NO. A27738

---

**AARTI PHARMALABS LIMITED**

[www.aartipharmalabs.com](http://www.aartipharmalabs.com) | CIN : L24100GJ2019PLC110964 | Email : [info@artipharmalabs.com](mailto:info@artipharmalabs.com)

**Admin Office :** 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234  
**Regd. Office :** Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655